7th Myeloid-Directed Summit 2025, November 18-20, 2025

Conference

genOway presentation

Event
-
November 18, 2025

genOway's presentation on Wednesday, November 19, 2025 | 11 a.m. EST:

How to enhance translatability of myeloid-targeted therapies in preclinical models

  • Human immune cells are recruited, differentiate and polarize in the tumor microenvironment (TME) of genO-BRGSF-HIS mouse model based on tumor type and tumor burden
  • genO-BRGSF-HIS mice recapitulates the pathophysiology of inflammatory diseases
  • genO-BRGSF-HIS mouse model is a valuable tool to investigate immune-related adverse events induced by immunotherapies

7th Myeloid-Directed Summit 2025, November 18-20, 2025

Get in touch

Let us know how we can help

Other news & events

The 55th Annual Meeting of the Japanese Society for Immunology, Osaka, November 17-19, 2026
Conference
genOway presentation
Event
-
Nov 2026
Read on
The 41st Annual Meeting of the Japanese Society for the Study of Xenobiotics in Tukuba, Japan, November 16-19, 2026
Conference
Event
-
Nov 2026
Read on
SITC meeting 2026, Phoenix, Arizona, November 4-8
Conference
genOway presentation
Event
-
Nov 2026
Read on
2nd T-Cell Engager for Autoimmune Disease Summit, Boston, October 27-29, 2026
Conference
genOway presentation
Event
-
Oct 2026
Read on
AusBiotech International Conference 2026, Queensland, October 21-23, 2026
Conference
genOway presentation
Event
-
Oct 2026
Read on
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe